Cortés-Guiral D, Hübner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91. https://doi.org/10.1038/s41572-021-00326-6.
Ren K, Xie X, Min T, et al. Development of the peritoneal metastasis: a review of back-grounds, mechanisms, treatments and prospects. J Clin Med. 2022;12(1):103. https://doi.org/10.3390/jcm12010103.
Article PubMed PubMed Central CAS Google Scholar
Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. J Gastrointest Oncol. 2016;7(1):143–57. https://doi.org/10.3978/j.issn.2078-6891.2015.112.
Article PubMed PubMed Central Google Scholar
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. https://doi.org/10.1002/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o.
Article PubMed CAS Google Scholar
Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363. https://doi.org/10.1001/jamasurg.2020.6363.
Article PubMed PubMed Central Google Scholar
Lurvink RJ, Villeneuve L, Govaerts K, et al. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol. 2021;47(1):4–10. https://doi.org/10.1016/j.ejso.2019.03.012.
Article PubMed CAS Google Scholar
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.
Steffen T, Häller L, Bijelic L, et al. Decision-making analysis for hyperthermic intraperitoneal chemotherapy in ovarian cancer: a survey by the executive committee of the peritoneal surface oncology group international (PSOGI). Oncology. 2021;99(1):41–8. https://doi.org/10.1159/000510098.
Kepenekian V, Bhatt A, Péron J, et al. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol. 2022;19(11):698–718. https://doi.org/10.1038/s41571-022-00675-5.
Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7. https://doi.org/10.1245/s10434-010-1039-7.
Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)30599-4.
Wang TY, Chen CY, Lu CH, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia. Int J Hyperthermia. 2018;34(3):328–35. https://doi.org/10.1080/02656736.2017.1337238.
Powers BD, Felder S, Veerapong J, et al. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is not associated with prohibitive complications: results of a multiinstitutional retrospective study. Ann Surg Oncol. 2020;27(13):4883–91. https://doi.org/10.1245/s10434-020-08482-x.
Dodson RM, McQuellon RP, Mogal HD, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(Suppl 5):772–83. https://doi.org/10.1245/s10434-016-5547-y.
Article PubMed PubMed Central Google Scholar
Stearns AT, Malcomson L, Punnett G, et al. Long-term quality of life after cytoreductive surgery and heated intraperitoneal chemotherapy for pseudomyxoma peritonei: a prospective longitudinal study. Ann Surg Oncol. 2018;25(4):965–73. https://doi.org/10.1245/s10434-017-6326-0.
Lee TC, Wima K, Sussman JJ, et al. Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a US HIPEC collaborative study. J Gastrointest Surg. 2020;24(1):165–76. https://doi.org/10.1007/s11605-019-04463-y.
Kelly KJ, Cajas L, Baumgartner JM, Lowy AM. Factors associated with 60-day readmission following cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(1):91–7.
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56. https://doi.org/10.1200/JCO.2011.39.7166.
van Oudheusden TR, Nienhuijs SW, Luyer MD, et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review. Eur J Surg Oncol. 2015;41(10):1269–77. https://doi.org/10.1016/j.ejso.2015.05.018.
Verwaal VJ, Boot H, Aleman BMP, van Tinteren H, Zoetmulder FAN. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375–9. https://doi.org/10.1245/ASO.2004.08.014.
Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol. 2016;7(1):129–42. https://doi.org/10.3978/j.issn.2078-6891.2015.131.
Article PubMed PubMed Central Google Scholar
Chimiohyperthermie intrapéritonéale (CHIP) associée ou non à une chirurgie de cytoreduction préalable. 2021. Available at: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/rapport_chip.pdf. Accessed 8 Feb 2023.
Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98(4):242–6. https://doi.org/10.1002/jso.21061.
Leiting JL, Cloyd JM, Ahmed A, et al. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020;12(7):756–67. https://doi.org/10.4251/wjgo.v12.i7.756.
Article PubMed PubMed Central Google Scholar
Bhatt A, de Hingh I, Van Der Speeten K, et al. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098–113. https://doi.org/10.1245/s10434-021-10193-w.
Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790–6. https://doi.org/10.1007/s10434-999-0790-0.
Article PubMed CAS Google Scholar
Fujimoto S, Shrestha RD, Kokubun M, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988;208(1):36–41. https://doi.org/10.1097/00000658-198807000-00005.
Article PubMed PubMed Central CAS Google Scholar
Cotte E, Passot G, Tod M, et al. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011;18(9):2599–603. https://doi.org/10.1245/s10434-011-1651-1.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.
Article PubMed PubMed Central Google Scholar
Cochran WG. The χ2 test of goodness of fit. Ann Math Stat. 1952;23(3):315–45.
留言 (0)